{
    "id": "dbpedia_9268_1",
    "rank": 69,
    "data": {
        "url": "https://patents.google.com/patent/WO2012128622A1/no",
        "read_more_link": "",
        "language": "en",
        "title": "WO2012128622A1 - Generation of nk cells and nk-cell progenitors - Google Patents",
        "top_image": "",
        "meta_img": "",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2011-03-18T00:00:00",
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://patents.google.com/patent/WO2012128622A1/no",
        "text": "Generation of nk cells and nk-cell progenitors Download PDF\n\nInfo\n\nPublication number\n\nWO2012128622A1\n\nWO2012128622A1 PCT/NL2012/050165 NL2012050165W WO2012128622A1 WO 2012128622 A1 WO2012128622 A1 WO 2012128622A1 NL 2012050165 W NL2012050165 W NL 2012050165W WO 2012128622 A1 WO2012128622 A1 WO 2012128622A1\n\nAuthority\n\nWO\n\nWIPO (PCT)\n\nPrior art keywords\n\ncells\n\ncell\n\nstage\n\ncollection\n\nculture\n\nPrior art date\n\n2011-03-18\n\nApplication number\n\nPCT/NL2012/050165\n\nOther languages\n\nEnglish (en)\n\nFrench (fr)\n\nInventor\n\nJan Spanholtz\n\nOriginal Assignee\n\nIpd-Therapeutics B.V.\n\nPriority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)\n\n2011-03-18\n\nFiling date\n\n2012-03-16\n\nPublication date\n\n2012-09-27\n\n2012-03-16 Application filed by Ipd-Therapeutics B.V. filed Critical Ipd-Therapeutics B.V.\n\n2012-03-16 Priority to EP12711984.0A priority Critical patent/EP2686421B1/en\n\n2012-03-16 Priority to CA2830080A priority patent/CA2830080C/en\n\n2012-03-16 Priority to DK12711984.0T priority patent/DK2686421T3/da\n\n2012-03-16 Priority to US14/005,168 priority patent/US11118165B2/en\n\n2012-03-16 Priority to PL12711984T priority patent/PL2686421T3/pl\n\n2012-03-16 Priority to ES12711984T priority patent/ES2856825T3/es\n\n2012-09-27 Publication of WO2012128622A1 publication Critical patent/WO2012128622A1/en\n\nLinks\n\nEspacenet\n\nGlobal Dossier\n\nPatentScope\n\nDiscuss\n\n210000000822 natural killer cell Anatomy 0.000 title claims abstract description 371\n\n210000004027 cell Anatomy 0.000 claims abstract description 524\n\n102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 119\n\n101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 119\n\n101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims abstract description 81\n\n102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims abstract description 81\n\n102000004127 Cytokines Human genes 0.000 claims abstract description 53\n\n108090000695 Cytokines Proteins 0.000 claims abstract description 53\n\n210000004748 cultured cell Anatomy 0.000 claims abstract description 41\n\n210000000130 stem cell Anatomy 0.000 claims description 124\n\n230000014509 gene expression Effects 0.000 claims description 109\n\n238000000034 method Methods 0.000 claims description 106\n\n239000002771 cell marker Substances 0.000 claims description 76\n\n101150069255 KLRC1 gene Proteins 0.000 claims description 54\n\n101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 54\n\n102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 54\n\n101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims description 51\n\n102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 51\n\n101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 44\n\n102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 44\n\n101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 42\n\n102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 42\n\n108010002586 Interleukin-7 Proteins 0.000 claims description 33\n\n229940100994 interleukin-7 Drugs 0.000 claims description 33\n\n239000001963 growth medium Substances 0.000 claims description 28\n\n108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 26\n\n108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 26\n\n102000004889 Interleukin-6 Human genes 0.000 claims description 26\n\n108090001005 Interleukin-6 Proteins 0.000 claims description 26\n\n238000012258 culturing Methods 0.000 claims description 26\n\n229940100601 interleukin-6 Drugs 0.000 claims description 26\n\n238000004519 manufacturing process Methods 0.000 claims description 25\n\n108010002350 Interleukin-2 Proteins 0.000 claims description 24\n\n102000000588 Interleukin-2 Human genes 0.000 claims description 24\n\n101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims description 23\n\n102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 23\n\n230000003068 static effect Effects 0.000 claims description 22\n\n210000001744 T-lymphocyte Anatomy 0.000 claims description 21\n\n229940127215 low-molecular weight heparin Drugs 0.000 claims description 21\n\n102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 20\n\n239000003055 low molecular weight heparin Substances 0.000 claims description 20\n\n102000003812 Interleukin-15 Human genes 0.000 claims description 19\n\n108090000172 Interleukin-15 Proteins 0.000 claims description 19\n\n210000002966 serum Anatomy 0.000 claims description 19\n\n238000003860 storage Methods 0.000 claims description 19\n\n101000577064 Lymnaea stagnalis Molluscan insulin-related peptide 1 Proteins 0.000 claims description 18\n\n101000737895 Mytilus edulis Contraction-inhibiting peptide 1 Proteins 0.000 claims description 18\n\n-1 CDl59a Proteins 0.000 claims description 16\n\n101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 16\n\n102100040120 Prominin-1 Human genes 0.000 claims description 16\n\n108700014844 flt3 ligand Proteins 0.000 claims description 16\n\n108091006905 Human Serum Albumin Proteins 0.000 claims description 15\n\n102000008100 Human Serum Albumin Human genes 0.000 claims description 15\n\n102000036693 Thrombopoietin Human genes 0.000 claims description 15\n\n108010041111 Thrombopoietin Proteins 0.000 claims description 15\n\n238000011161 development Methods 0.000 claims description 13\n\n208000032839 leukemia Diseases 0.000 claims description 12\n\n210000004962 mammalian cell Anatomy 0.000 claims description 12\n\n102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 11\n\n102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims description 8\n\n108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims description 8\n\n238000002156 mixing Methods 0.000 claims description 5\n\n239000007787 solid Substances 0.000 claims description 5\n\n102100025390 Integrin beta-2 Human genes 0.000 claims description 4\n\n102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 3\n\n239000000306 component Substances 0.000 claims description 3\n\n108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 2\n\n101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2\n\n108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 2\n\n102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 10\n\n102000000704 Interleukin-7 Human genes 0.000 claims 10\n\n101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims 3\n\n102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 3\n\n101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1\n\n101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1\n\n102000003729 Neprilysin Human genes 0.000 claims 1\n\n108090000028 Neprilysin Proteins 0.000 claims 1\n\n102100027208 T-cell antigen CD7 Human genes 0.000 claims 1\n\n238000004113 cell culture Methods 0.000 abstract description 15\n\n210000003958 hematopoietic stem cell Anatomy 0.000 abstract description 7\n\n238000012136 culture method Methods 0.000 abstract description 4\n\n210000004700 fetal blood Anatomy 0.000 description 120\n\n210000001519 tissue Anatomy 0.000 description 113\n\n210000001185 bone marrow Anatomy 0.000 description 100\n\n239000011886 peripheral blood Substances 0.000 description 80\n\n210000005259 peripheral blood Anatomy 0.000 description 80\n\n238000011124 ex vivo culture Methods 0.000 description 68\n\n210000000952 spleen Anatomy 0.000 description 67\n\n239000000047 product Substances 0.000 description 64\n\n238000004458 analytical method Methods 0.000 description 32\n\n229910052757 nitrogen Inorganic materials 0.000 description 30\n\n229910052700 potassium Inorganic materials 0.000 description 28\n\nHTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 27\n\n229920000669 heparin Polymers 0.000 description 27\n\n210000001165 lymph node Anatomy 0.000 description 27\n\n206010028980 Neoplasm Diseases 0.000 description 24\n\n229910052698 phosphorus Inorganic materials 0.000 description 24\n\n102100021592 Interleukin-7 Human genes 0.000 description 23\n\n238000002659 cell therapy Methods 0.000 description 23\n\n210000004185 liver Anatomy 0.000 description 21\n\n230000004069 differentiation Effects 0.000 description 20\n\n238000001727 in vivo Methods 0.000 description 20\n\n239000002609 medium Substances 0.000 description 20\n\n238000005406 washing Methods 0.000 description 19\n\n210000004369 blood Anatomy 0.000 description 18\n\n239000008280 blood Substances 0.000 description 18\n\n230000011712 cell development Effects 0.000 description 18\n\n229960002897 heparin Drugs 0.000 description 18\n\n238000001802 infusion Methods 0.000 description 18\n\n201000011510 cancer Diseases 0.000 description 17\n\n239000003550 marker Substances 0.000 description 17\n\n239000000243 solution Substances 0.000 description 17\n\n102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 16\n\n238000000684 flow cytometry Methods 0.000 description 16\n\n238000002054 transplantation Methods 0.000 description 16\n\n102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 15\n\n102000005962 receptors Human genes 0.000 description 15\n\n108020003175 receptors Proteins 0.000 description 15\n\n230000024245 cell differentiation Effects 0.000 description 14\n\n230000000694 effects Effects 0.000 description 14\n\n230000008569 process Effects 0.000 description 14\n\n102000010648 Natural Killer Cell Receptors Human genes 0.000 description 13\n\n238000011282 treatment Methods 0.000 description 13\n\n108091008877 NK cell receptors Proteins 0.000 description 12\n\n108090000623 proteins and genes Proteins 0.000 description 12\n\n230000002829 reductive effect Effects 0.000 description 12\n\n238000012360 testing method Methods 0.000 description 12\n\n108010043610 KIR Receptors Proteins 0.000 description 11\n\n102000002698 KIR Receptors Human genes 0.000 description 11\n\n229910052796 boron Inorganic materials 0.000 description 11\n\n230000010261 cell growth Effects 0.000 description 11\n\n230000018109 developmental process Effects 0.000 description 11\n\n238000011084 recovery Methods 0.000 description 11\n\n101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 10\n\n102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 10\n\n238000009169 immunotherapy Methods 0.000 description 10\n\n210000004698 lymphocyte Anatomy 0.000 description 10\n\n230000011748 cell maturation Effects 0.000 description 9\n\n210000002889 endothelial cell Anatomy 0.000 description 9\n\n238000000338 in vitro Methods 0.000 description 9\n\n230000035899 viability Effects 0.000 description 9\n\n102000013462 Interleukin-12 Human genes 0.000 description 8\n\n108010065805 Interleukin-12 Proteins 0.000 description 8\n\n102000003810 Interleukin-18 Human genes 0.000 description 8\n\n108090000171 Interleukin-18 Proteins 0.000 description 8\n\n102100030704 Interleukin-21 Human genes 0.000 description 8\n\n239000000427 antigen Substances 0.000 description 8\n\n108091007433 antigens Proteins 0.000 description 8\n\n102000036639 antigens Human genes 0.000 description 8\n\n108010074108 interleukin-21 Proteins 0.000 description 8\n\n238000011476 stem cell transplantation Methods 0.000 description 8\n\n102000003815 Interleukin-11 Human genes 0.000 description 7\n\n108090000177 Interleukin-11 Proteins 0.000 description 7\n\n102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 7\n\n239000000872 buffer Substances 0.000 description 7\n\n230000001461 cytolytic effect Effects 0.000 description 7\n\n238000011065 in-situ storage Methods 0.000 description 7\n\n230000002401 inhibitory effect Effects 0.000 description 7\n\n102000004169 proteins and genes Human genes 0.000 description 7\n\n238000010257 thawing Methods 0.000 description 7\n\nIJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6\n\n101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 6\n\n102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 6\n\n102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 6\n\n230000003213 activating effect Effects 0.000 description 6\n\n231100000433 cytotoxic Toxicity 0.000 description 6\n\n230000001472 cytotoxic effect Effects 0.000 description 6\n\n201000010099 disease Diseases 0.000 description 6\n\n208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6\n\n230000004048 modification Effects 0.000 description 6\n\n238000012986 modification Methods 0.000 description 6\n\n210000005087 mononuclear cell Anatomy 0.000 description 6\n\n230000004936 stimulating effect Effects 0.000 description 6\n\n208000031261 Acute myeloid leukaemia Diseases 0.000 description 5\n\n229920002683 Glycosaminoglycan Polymers 0.000 description 5\n\n241000282412 Homo Species 0.000 description 5\n\n108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 5\n\nFAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5\n\n230000000735 allogeneic effect Effects 0.000 description 5\n\n230000001580 bacterial effect Effects 0.000 description 5\n\n230000008901 benefit Effects 0.000 description 5\n\n238000005138 cryopreservation Methods 0.000 description 5\n\n238000001514 detection method Methods 0.000 description 5\n\n238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 5\n\n238000009826 distribution Methods 0.000 description 5\n\n210000003743 erythrocyte Anatomy 0.000 description 5\n\n238000011194 good manufacturing practice Methods 0.000 description 5\n\n238000007477 logistic regression Methods 0.000 description 5\n\n230000035800 maturation Effects 0.000 description 5\n\n239000012266 salt solution Substances 0.000 description 5\n\n238000000926 separation method Methods 0.000 description 5\n\n239000006144 Dulbeccoâs modiï¬ed Eagle's medium Substances 0.000 description 4\n\nKCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4\n\nMHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4\n\n108010065637 Interleukin-23 Proteins 0.000 description 4\n\n241000204031 Mycoplasma Species 0.000 description 4\n\n208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4\n\n108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 4\n\n230000004913 activation Effects 0.000 description 4\n\n238000003776 cleavage reaction Methods 0.000 description 4\n\n238000011109 contamination Methods 0.000 description 4\n\n231100000135 cytotoxicity Toxicity 0.000 description 4\n\n230000003013 cytotoxicity Effects 0.000 description 4\n\n230000007423 decrease Effects 0.000 description 4\n\n239000002158 endotoxin Substances 0.000 description 4\n\n238000005516 engineering process Methods 0.000 description 4\n\n230000007717 exclusion Effects 0.000 description 4\n\n238000002474 experimental method Methods 0.000 description 4\n\n230000002538 fungal effect Effects 0.000 description 4\n\n230000002607 hemopoietic effect Effects 0.000 description 4\n\n230000004957 immunoregulator effect Effects 0.000 description 4\n\n108091008042 inhibitory receptors Proteins 0.000 description 4\n\n210000001939 mature NK cell Anatomy 0.000 description 4\n\n230000002035 prolonged effect Effects 0.000 description 4\n\n230000001105 regulatory effect Effects 0.000 description 4\n\n230000007017 scission Effects 0.000 description 4\n\n238000013112 stability test Methods 0.000 description 4\n\n238000010200 validation analysis Methods 0.000 description 4\n\n238000002965 ELISA Methods 0.000 description 3\n\n208000009329 Graft vs Host Disease Diseases 0.000 description 3\n\n101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 3\n\n230000006051 NK cell activation Effects 0.000 description 3\n\n102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 3\n\n206010044696 Tropical spastic paresis Diseases 0.000 description 3\n\n238000000540 analysis of variance Methods 0.000 description 3\n\n210000003719 b-lymphocyte Anatomy 0.000 description 3\n\n230000003915 cell function Effects 0.000 description 3\n\n239000007795 chemical reaction product Substances 0.000 description 3\n\n238000003501 co-culture Methods 0.000 description 3\n\n230000002559 cytogenic effect Effects 0.000 description 3\n\n230000009089 cytolysis Effects 0.000 description 3\n\n108010067396 dornase alfa Proteins 0.000 description 3\n\n230000006870 function Effects 0.000 description 3\n\n208000024908 graft versus host disease Diseases 0.000 description 3\n\n210000003509 immature nk cell Anatomy 0.000 description 3\n\n238000011534 incubation Methods 0.000 description 3\n\n238000002347 injection Methods 0.000 description 3\n\n239000007924 injection Substances 0.000 description 3\n\n239000007788 liquid Substances 0.000 description 3\n\n210000003563 lymphoid tissue Anatomy 0.000 description 3\n\n239000000203 mixture Substances 0.000 description 3\n\n239000002243 precursor Substances 0.000 description 3\n\n238000002360 preparation method Methods 0.000 description 3\n\n238000012545 processing Methods 0.000 description 3\n\n229940107568 pulmozyme Drugs 0.000 description 3\n\n238000000746 purification Methods 0.000 description 3\n\n238000010187 selection method Methods 0.000 description 3\n\n230000004083 survival effect Effects 0.000 description 3\n\n230000002459 sustained effect Effects 0.000 description 3\n\n238000002560 therapeutic procedure Methods 0.000 description 3\n\n230000032258 transport Effects 0.000 description 3\n\n208000023275 Autoimmune disease Diseases 0.000 description 2\n\n241001227713 Chiron Species 0.000 description 2\n\n102000001398 Granzyme Human genes 0.000 description 2\n\n108060005986 Granzyme Proteins 0.000 description 2\n\n102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 2\n\n101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 2\n\n101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2\n\n229920001612 Hydroxyethyl starch Polymers 0.000 description 2\n\n239000012480 LAL reagent Substances 0.000 description 2\n\n108700018351 Major Histocompatibility Complex Proteins 0.000 description 2\n\n102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2\n\n108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 description 2\n\n102000000834 NK Cell Lectin-Like Receptor Subfamily C Human genes 0.000 description 2\n\n238000011789 NOD SCID mouse Methods 0.000 description 2\n\n102000007562 Serum Albumin Human genes 0.000 description 2\n\n108010071390 Serum Albumin Proteins 0.000 description 2\n\n102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2\n\n108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2\n\n208000007536 Thrombosis Diseases 0.000 description 2\n\n229940127174 UCHT1 Drugs 0.000 description 2\n\n241000700605 Viruses Species 0.000 description 2\n\n239000000654 additive Substances 0.000 description 2\n\n108700025316 aldesleukin Proteins 0.000 description 2\n\n239000003146 anticoagulant agent Substances 0.000 description 2\n\n229940127219 anticoagulant drug Drugs 0.000 description 2\n\n239000002246 antineoplastic agent Substances 0.000 description 2\n\n238000003556 assay Methods 0.000 description 2\n\n230000001413 cellular effect Effects 0.000 description 2\n\n238000012512 characterization method Methods 0.000 description 2\n\n230000000052 comparative effect Effects 0.000 description 2\n\n210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2\n\n229940127089 cytotoxic agent Drugs 0.000 description 2\n\n230000000779 depleting effect Effects 0.000 description 2\n\n238000011143 downstream manufacturing Methods 0.000 description 2\n\n239000012636 effector Substances 0.000 description 2\n\n238000010195 expression analysis Methods 0.000 description 2\n\n230000001605 fetal effect Effects 0.000 description 2\n\n238000005194 fractionation Methods 0.000 description 2\n\n230000002068 genetic effect Effects 0.000 description 2\n\n239000003102 growth factor Substances 0.000 description 2\n\n230000003394 haemopoietic effect Effects 0.000 description 2\n\n229940050526 hydroxyethylstarch Drugs 0.000 description 2\n\n229940124622 immune-modulator drug Drugs 0.000 description 2\n\n208000015181 infectious disease Diseases 0.000 description 2\n\n230000000977 initiatory effect Effects 0.000 description 2\n\n230000015788 innate immune response Effects 0.000 description 2\n\n238000001990 intravenous administration Methods 0.000 description 2\n\n238000002955 isolation Methods 0.000 description 2\n\n210000003734 kidney Anatomy 0.000 description 2\n\n230000000503 lectinlike effect Effects 0.000 description 2\n\n210000000265 leukocyte Anatomy 0.000 description 2\n\n230000000670 limiting effect Effects 0.000 description 2\n\n230000036210 malignancy Effects 0.000 description 2\n\n239000000463 material Substances 0.000 description 2\n\n238000005259 measurement Methods 0.000 description 2\n\n230000001404 mediated effect Effects 0.000 description 2\n\n238000010899 nucleation Methods 0.000 description 2\n\n230000001590 oxidative effect Effects 0.000 description 2\n\n244000052769 pathogen Species 0.000 description 2\n\n230000001717 pathogenic effect Effects 0.000 description 2\n\n230000037361 pathway Effects 0.000 description 2\n\n238000010837 poor prognosis Methods 0.000 description 2\n\n229940087463 proleukin Drugs 0.000 description 2\n\n238000003908 quality control method Methods 0.000 description 2\n\n238000012429 release testing Methods 0.000 description 2\n\n238000011160 research Methods 0.000 description 2\n\n238000012552 review Methods 0.000 description 2\n\n238000004062 sedimentation Methods 0.000 description 2\n\n239000011780 sodium chloride Substances 0.000 description 2\n\n230000003393 splenic effect Effects 0.000 description 2\n\n238000007619 statistical method Methods 0.000 description 2\n\nUCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2\n\n239000006228 supernatant Substances 0.000 description 2\n\n230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2\n\n210000004881 tumor cell Anatomy 0.000 description 2\n\n239000011534 wash buffer Substances 0.000 description 2\n\nUZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1\n\n108091008875 B cell receptors Proteins 0.000 description 1\n\n102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1\n\n108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1\n\n102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1\n\n241000894006 Bacteria Species 0.000 description 1\n\n108091003079 Bovine Serum Albumin Proteins 0.000 description 1\n\n102000003930 C-Type Lectins Human genes 0.000 description 1\n\n108090000342 C-Type Lectins Proteins 0.000 description 1\n\n238000011740 C57BL/6 mouse Methods 0.000 description 1\n\n102100024209 CD177 antigen Human genes 0.000 description 1\n\n108010003639 CD56 Antigen Proteins 0.000 description 1\n\n102000004652 CD56 Antigen Human genes 0.000 description 1\n\n208000035473 Communicable disease Diseases 0.000 description 1\n\n108010049207 Death Domain Receptors Proteins 0.000 description 1\n\n102000009058 Death Domain Receptors Human genes 0.000 description 1\n\n241000588724 Escherichia coli Species 0.000 description 1\n\n108010029961 Filgrastim Proteins 0.000 description 1\n\n102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1\n\n101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1\n\n241000237858 Gastropoda Species 0.000 description 1\n\n239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 1\n\n108010022901 Heparin Lyase Proteins 0.000 description 1\n\n101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1\n\n101000980845 Homo sapiens CD177 antigen Proteins 0.000 description 1\n\n101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1\n\n101000945335 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5B Proteins 0.000 description 1\n\n101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 description 1\n\n101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 1\n\n101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1\n\n101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1\n\n101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1\n\n102000013691 Interleukin-17 Human genes 0.000 description 1\n\n108050003558 Interleukin-17 Proteins 0.000 description 1\n\n102000013264 Interleukin-23 Human genes 0.000 description 1\n\n239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1\n\n102100033628 Killer cell immunoglobulin-like receptor 2DL5B Human genes 0.000 description 1\n\n102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 1\n\n102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1\n\n206010025323 Lymphomas Diseases 0.000 description 1\n\n102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1\n\n241000124008 Mammalia Species 0.000 description 1\n\n208000034578 Multiple myelomas Diseases 0.000 description 1\n\n241000699670 Mus sp. Species 0.000 description 1\n\n108010001605 NK Cell Lectin-Like Receptor Subfamily D Proteins 0.000 description 1\n\n108010077854 Natural Killer Cell Receptors Proteins 0.000 description 1\n\n206010061308 Neonatal infection Diseases 0.000 description 1\n\nIOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1\n\n102000014736 Notch Human genes 0.000 description 1\n\n108010070047 Notch Receptors Proteins 0.000 description 1\n\n102100037603 P2X purinoceptor 5 Human genes 0.000 description 1\n\n101710189969 P2X purinoceptor 5 Proteins 0.000 description 1\n\n229930182555 Penicillin Natural products 0.000 description 1\n\nJGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1\n\nKHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1\n\n206010035226 Plasma cell myeloma Diseases 0.000 description 1\n\n206010060862 Prostate cancer Diseases 0.000 description 1\n\n208000000236 Prostatic Neoplasms Diseases 0.000 description 1\n\n108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1\n\n102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1\n\n108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1\n\n102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1\n\n239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1\n\n108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 1\n\n102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 description 1\n\n238000000692 Student's t-test Methods 0.000 description 1\n\n206010052779 Transplant rejections Diseases 0.000 description 1\n\n102000004142 Trypsin Human genes 0.000 description 1\n\n108090000631 Trypsin Proteins 0.000 description 1\n\n208000036142 Viral infection Diseases 0.000 description 1\n\n230000005856 abnormality Effects 0.000 description 1\n\n230000021736 acetylation Effects 0.000 description 1\n\n238000006640 acetylation reaction Methods 0.000 description 1\n\n230000006978 adaptation Effects 0.000 description 1\n\n230000004721 adaptive immunity Effects 0.000 description 1\n\n230000000996 additive effect Effects 0.000 description 1\n\n230000000259 anti-tumor effect Effects 0.000 description 1\n\n230000006023 anti-tumor response Effects 0.000 description 1\n\n230000009833 antibody interaction Effects 0.000 description 1\n\n238000003782 apoptosis assay Methods 0.000 description 1\n\n230000006907 apoptotic process Effects 0.000 description 1\n\n229940090880 ardeparin Drugs 0.000 description 1\n\n239000007640 basal medium Substances 0.000 description 1\n\n230000008033 biological extinction Effects 0.000 description 1\n\n230000033228 biological regulation Effects 0.000 description 1\n\n239000010836 blood and blood product Substances 0.000 description 1\n\n229940125691 blood product Drugs 0.000 description 1\n\n230000037396 body weight Effects 0.000 description 1\n\n238000010322 bone marrow transplantation Methods 0.000 description 1\n\n238000002619 cancer immunotherapy Methods 0.000 description 1\n\n239000006285 cell suspension Substances 0.000 description 1\n\n230000005754 cellular signaling Effects 0.000 description 1\n\n238000005119 centrifugation Methods 0.000 description 1\n\n229940107792 certoparin Drugs 0.000 description 1\n\n230000008859 change Effects 0.000 description 1\n\n239000003153 chemical reaction reagent Substances 0.000 description 1\n\n238000002512 chemotherapy Methods 0.000 description 1\n\n238000009104 chemotherapy regimen Methods 0.000 description 1\n\n201000002687 childhood acute myeloid leukemia Diseases 0.000 description 1\n\n239000011248 coating agent Substances 0.000 description 1\n\n238000000576 coating method Methods 0.000 description 1\n\n230000016396 cytokine production Effects 0.000 description 1\n\n210000004395 cytoplasmic granule Anatomy 0.000 description 1\n\n238000002784 cytotoxicity assay Methods 0.000 description 1\n\n231100000263 cytotoxicity test Toxicity 0.000 description 1\n\n229960004969 dalteparin Drugs 0.000 description 1\n\n229940029030 dendritic cell vaccine Drugs 0.000 description 1\n\n238000000432 density-gradient centrifugation Methods 0.000 description 1\n\n230000001627 detrimental effect Effects 0.000 description 1\n\n206010012601 diabetes mellitus Diseases 0.000 description 1\n\n239000003085 diluting agent Substances 0.000 description 1\n\n238000010790 dilution Methods 0.000 description 1\n\n239000012895 dilution Substances 0.000 description 1\n\n231100000673 doseâresponse relationship Toxicity 0.000 description 1\n\n230000002121 endocytic effect Effects 0.000 description 1\n\n230000012202 endocytosis Effects 0.000 description 1\n\n229960000610 enoxaparin Drugs 0.000 description 1\n\n239000012894 fetal calf serum Substances 0.000 description 1\n\n239000013020 final formulation Substances 0.000 description 1\n\n239000012467 final product Substances 0.000 description 1\n\n238000009472 formulation Methods 0.000 description 1\n\n229940087051 fragmin Drugs 0.000 description 1\n\n239000012737 fresh medium Substances 0.000 description 1\n\n230000005714 functional activity Effects 0.000 description 1\n\n239000007789 gas Substances 0.000 description 1\n\n150000004676 glycans Chemical class 0.000 description 1\n\n230000012010 growth Effects 0.000 description 1\n\n238000003306 harvesting Methods 0.000 description 1\n\n230000036541 health Effects 0.000 description 1\n\n230000007407 health benefit Effects 0.000 description 1\n\n230000002489 hematologic effect Effects 0.000 description 1\n\n238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1\n\n208000006454 hepatitis Diseases 0.000 description 1\n\n231100000283 hepatitis Toxicity 0.000 description 1\n\n230000004046 hyporesponsiveness Effects 0.000 description 1\n\n230000036039 immunity Effects 0.000 description 1\n\n238000013394 immunophenotyping Methods 0.000 description 1\n\n239000003018 immunosuppressive agent Substances 0.000 description 1\n\n229940124589 immunosuppressive drug Drugs 0.000 description 1\n\n230000001771 impaired effect Effects 0.000 description 1\n\n230000001976 improved effect Effects 0.000 description 1\n\n229910052738 indium Inorganic materials 0.000 description 1\n\nAPFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1\n\n210000005007 innate immune system Anatomy 0.000 description 1\n\n229940095443 innohep Drugs 0.000 description 1\n\n238000010253 intravenous injection Methods 0.000 description 1\n\n238000011835 investigation Methods 0.000 description 1\n\nOWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1\n\n230000002147 killing effect Effects 0.000 description 1\n\n238000002372 labelling Methods 0.000 description 1\n\n238000011173 large scale experimental method Methods 0.000 description 1\n\n239000003446 ligand Substances 0.000 description 1\n\n201000007270 liver cancer Diseases 0.000 description 1\n\n208000014018 liver neoplasm Diseases 0.000 description 1\n\n229940118179 lovenox Drugs 0.000 description 1\n\n210000003738 lymphoid progenitor cell Anatomy 0.000 description 1\n\n230000003211 malignant effect Effects 0.000 description 1\n\n230000007246 mechanism Effects 0.000 description 1\n\n210000002901 mesenchymal stem cell Anatomy 0.000 description 1\n\n230000031864 metaphase Effects 0.000 description 1\n\n210000004877 mucosa Anatomy 0.000 description 1\n\n229960000899 nadroparin Drugs 0.000 description 1\n\n210000000581 natural killer T-cell Anatomy 0.000 description 1\n\n229940029345 neupogen Drugs 0.000 description 1\n\n229960004762 parnaparin Drugs 0.000 description 1\n\n229940049954 penicillin Drugs 0.000 description 1\n\n229930192851 perforin Natural products 0.000 description 1\n\n230000000737 periodic effect Effects 0.000 description 1\n\n230000002093 peripheral effect Effects 0.000 description 1\n\n210000004303 peritoneum Anatomy 0.000 description 1\n\n238000009520 phase I clinical trial Methods 0.000 description 1\n\n230000026731 phosphorylation Effects 0.000 description 1\n\n238000006366 phosphorylation reaction Methods 0.000 description 1\n\n230000003169 placental effect Effects 0.000 description 1\n\n229920001282 polysaccharide Polymers 0.000 description 1\n\n239000005017 polysaccharide Substances 0.000 description 1\n\n210000003240 portal vein Anatomy 0.000 description 1\n\n230000035935 pregnancy Effects 0.000 description 1\n\n230000005522 programmed cell death Effects 0.000 description 1\n\n238000011321 prophylaxis Methods 0.000 description 1\n\n229940034080 provenge Drugs 0.000 description 1\n\n230000009467 reduction Effects 0.000 description 1\n\n230000004044 response Effects 0.000 description 1\n\n229960005496 reviparin Drugs 0.000 description 1\n\n239000011435 rock Substances 0.000 description 1\n\n230000035945 sensitivity Effects 0.000 description 1\n\n238000002603 single-photon emission computed tomography Methods 0.000 description 1\n\n210000003491 skin Anatomy 0.000 description 1\n\n210000004927 skin cell Anatomy 0.000 description 1\n\nYEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1\n\n210000001988 somatic stem cell Anatomy 0.000 description 1\n\n230000003595 spectral effect Effects 0.000 description 1\n\n238000010186 staining Methods 0.000 description 1\n\n238000010561 standard procedure Methods 0.000 description 1\n\n238000013190 sterility testing Methods 0.000 description 1\n\n229960005322 streptomycin Drugs 0.000 description 1\n\n239000000126 substance Substances 0.000 description 1\n\n230000003319 supportive effect Effects 0.000 description 1\n\n238000001356 surgical procedure Methods 0.000 description 1\n\n230000001225 therapeutic effect Effects 0.000 description 1\n\nSYRHIZPPCHMRIT-UHFFFAOYSA-N tin(4+) Chemical compound [Sn+4] SYRHIZPPCHMRIT-UHFFFAOYSA-N 0.000 description 1\n\n229960005062 tinzaparin Drugs 0.000 description 1\n\n230000001988 toxicity Effects 0.000 description 1\n\n231100000419 toxicity Toxicity 0.000 description 1\n\n238000012546 transfer Methods 0.000 description 1\n\n238000013520 translational research Methods 0.000 description 1\n\n239000012588 trypsin Substances 0.000 description 1\n\n210000003954 umbilical cord Anatomy 0.000 description 1\n\n230000009385 viral infection Effects 0.000 description 1\n\n230000003612 virological effect Effects 0.000 description 1\n\n230000003442 weekly effect Effects 0.000 description 1\n\nClassifications\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor\n\nC12N5/06—Animal cells or tissues; Human cells or tissues\n\nC12N5/0602—Vertebrate cells\n\nC12N5/0634—Cells from the blood or the immune system\n\nC12N5/0646—Natural killers cells [NK], NKT cells\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N2501/00—Active agents used in cell culture processes, e.g. differentation\n\nC12N2501/10—Growth factors\n\nC12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N2501/00—Active agents used in cell culture processes, e.g. differentation\n\nC12N2501/10—Growth factors\n\nC12N2501/145—Thrombopoietin [TPO]\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N2501/00—Active agents used in cell culture processes, e.g. differentation\n\nC12N2501/20—Cytokines; Chemokines\n\nC12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N2501/00—Active agents used in cell culture processes, e.g. differentation\n\nC12N2501/20—Cytokines; Chemokines\n\nC12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N2501/00—Active agents used in cell culture processes, e.g. differentation\n\nC12N2501/20—Cytokines; Chemokines\n\nC12N2501/23—Interleukins [IL]\n\nC12N2501/2302—Interleukin-2 (IL-2)\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N2501/00—Active agents used in cell culture processes, e.g. differentation\n\nC12N2501/20—Cytokines; Chemokines\n\nC12N2501/23—Interleukins [IL]\n\nC12N2501/2306—Interleukin-6 (IL-6)\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N2501/00—Active agents used in cell culture processes, e.g. differentation\n\nC12N2501/20—Cytokines; Chemokines\n\nC12N2501/23—Interleukins [IL]\n\nC12N2501/2307—Interleukin-7 (IL-7)\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N2501/00—Active agents used in cell culture processes, e.g. differentation\n\nC12N2501/20—Cytokines; Chemokines\n\nC12N2501/23—Interleukins [IL]\n\nC12N2501/2315—Interleukin-15 (IL-15)\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N2501/00—Active agents used in cell culture processes, e.g. differentation\n\nC12N2501/20—Cytokines; Chemokines\n\nC12N2501/23—Interleukins [IL]\n\nC12N2501/235—Leukemia inhibitory factor [LIF]\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N2501/00—Active agents used in cell culture processes, e.g. differentation\n\nC12N2501/20—Cytokines; Chemokines\n\nC12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA\n\nC12N2501/00—Active agents used in cell culture processes, e.g. differentation\n\nC12N2501/90—Polysaccharides\n\nC12N2501/91—Heparin\n\nDefinitions\n\nthe invention provides a method for producing a collection of natural killer (NK) cells said method comprising\n\nstep (i) culturing said cells of step (i) at a cell density of at least 0.5 x\n\na particularly preferred source is human cord blood.\n\nsaid source is a source of frozen human cord blood.\n\nMany basic media are known. A selection is given below, but many more may be suitable.\n\nBasic media include but are not limited to BEM (Basic Eagle Medium), DMEM (Dulbecco's modified Eagle Medium), Glasgow minimal essential medium, M199 basal medium, HAMs F-10, HAMs F-12, Iscove's DMEM, RPMI, Leibovitz L15, MCDB, McCoy 5A StemSpan H3000Â® and StemSpanSFEMÂ®, Stemline ITM and Stemline IITM, Glycostem Basal growth medium (GBGMTM); X-VivolOTM, X-Vivol5TM and X-Vivo20TM etc.\n\nSPL, inLN and LiLN share the central P subset and in LiLN also the N subset is central.\n\nthe K subset is central in BM, CB and PB, it is exclusive for ex-vivo cultures compared to SPL, inLN and LiLN.\n\nEx-vivo cultures have exclusive subsets E, M compared with BM for week 1-3 and share P in the 1st week of culture and N subset for week 1-3.\n\nEx-vivo cultures have exclusive subsets E, M, N, K compared with SPL in week 1-3 and subset K in week 4+5.\n\nEx-vivo cultures have exclusive subsets B, M, N, K, P compared with PB for week 3, B, M, N and K for week 4 of culture. B, M, K subsets are exclusively seen in week 5 of ex-vivo cultures.\n\nEx-vivo cultures have exclusive subsets B, M, N, K, P compared with SPL for week 3, B, M, N and K for week 4 of culture.\n\nB, M, K subsets are exclusively seen in week 5 of ex-vivo cultures.\n\nEx-vivo cultures have exclusive subsets B, M, N, K compared with inLN for week 3, and 4 and P subset is shared in the 4th week of culture.\n\nB, M, K subsets are exclusively seen in week 5 of ex-vivo cultures.\n\nNK cells can be educated locally to kill the cancer cells.\n\nStage 3b cells and subsets thereof are very well suited for NK cell lineage specific manipulation by GAGs, heparins cytokines, or other proteins.\n\nStage 4 cells are found in various tissues such as BM, CB, peripheral blood\n\nStage 5b cells are found in various tissues such as BM, CB, peripheral blood (PB), spleen (SPL), inguinal lymph nodes (inLN), liver lymph nodes (LiLN) and during ex-vivo NK cell generation.\n\nBM, CB, PB, SPL, inLN and LiLN share a central main subset M, which is present during 3 weeks of NK cell differentiation (week 3-5). In BM, CB and PB they share additionally the central small subset K compared to week 3-5 of culture.\n\nEx-vivo cultures have exclusive subset B compared with BM, CB and PB during 3rd and 5th week of culture. J subset is shared in week 4+5 of ex-vivo cultures.\n\nthe invention further provides a method of the invention further comprising obtaining a cell sample of said culture of step (ii), step (iia) and/or step (iii) and determining stages of NK development in cells of said culture.\n\nthe culture of step (ii), step (iia) or step (iii) is terminated on the basis of a detected developmental stage in said sample.\n\nNK cells are transfused to another individual as the individual from which the stem or progenitor cells were harvested, that the collection is essentially free of CD 3+ T cells.\n\nCD 3+ T cells can induce life threatening conditions, such as Graft versus Host disease.\n\na collection of harvested cultured cells according to the invention is provided, wherein the collection is essentially free of CD3+ T cells.\n\nNK cells or progenitor cells thereof have different properties depending on the developmental stage of the NK-cells or the progenitor. The fact that a culture system as provided by the invention provides NK cells and progenitors thereof at various developmental stages can be used to tailor a graft to the specific need of the individual to be treated with the graft.\n\nthe present invention provides a method for determining a developmental stage of NK development, said method comprising - obtaining a cell sample of said culture of step (ii), step (iia) and/or step (iii),\n\nmarkers for said stages are CD34, CD 117, CD56 and CD94.\n\nthe combination of CD34, CD 117, CD56 and CD94 is very useful in determining the developmental stage of NK cells or NK progenitor cells. Now that the invention has shown that these 7 developmental stage exist also other markers can be used to identify the detected developmental stages.\n\nthe invention provides a method according to the invention, wherein said developmental stage of NK development is classified as stage 1, 2, 3a, 3b, 4, 5a, and 5b by measuring the expression of surface markers CD34, CD 117, CD56, and CD94, wherein\n\nstage 5a is characterized by cells having the expression profile CD34 negative, CD 117 negative, CD56 positive, CD94 positive,\n\nstage 3b is further characterized by cells negative for CD 133, CD33, and NKG2A expression,\n\nFIG. 1 Ex-vivo generation of CD56 + NK cells from cryop reserved CD34 + UCB cells.\n\nCD34-enriched UCB cells were expanded for two weeks and subsequently differentiated into NK cells for four additional weeks. Cell cultures were weekly analyzed for cell numbers and phenotype using flow cytometry.\n\nA Fold expansion of total cells for each donor after initial seeding of enriched CD34 + UCB cells during 6 weeks of culture using static VuelifeTM cell culture bags.\n\nB CD56 + cell frequency for each donor during the 6 week culture period for static bag cultures.\n\nC Fold expansion of total cells for each donor after initial seeding of enriched CD34 + UCB cell population during 6 weeks of culture using single use bioreactors.\n\nFIG. 3 Flow cytometry analysis of ex vivo bioreactor-expanded NK cells before and after washing.\n\nthe CD56 + CD3- lymphocytes were analyzed of unwashed (A) and washed (B) NK cell products were analyzed.\n\nA unwashed\n\nB washed\n\nFIG. 1 Cells from four different donors (A, B, C, and D) were ex-vivo cultured in a bioreactor. Depicted are the percentage cells positive for expression of the indicated marker after culture, washing and after storage at 4Â°C for 1, 2 or 3 days as indicated.\n\nFigure 8. Expression of several genes from PB dim and bright NK cells, activated PB NK cells to the expression of ex vivo generated NK cells.\n\nCell populations > 0.1% of the CD45 + CD3- population with a threshold of more than 50 cells were considered reliable. Cell populations were considered tissue specific when at least 3 out of 5 samples showed reliable results. Cell populations that did not suffice to these criteria were excluded from further (statistical) analysis. Shown in this figure are all NK cell developmental stages within each tissue.\n\nBM bone marrow\n\nCB cord blood\n\nPB peripheral blood\n\ninLN inguinal LN\n\nliver LN liver LN\n\nSPL spleen\n\nCell populations > 0.1% of the CD45 + CD3\" population with a threshold of more than 50 cells were considered reliable.\n\nCell populations were considered tissue specific when at least 3 out of 5 samples showed reliable results.\n\nCell populations that did not suffice to these criteria were excluded from further (statistical) analysis. Shown in this figure are all NK cell developmental stages within each tissue. Comparison between the different tissues was analyzed using a random effect logistic regression model; *P â 05, **P â 01, ***P â 0001.\n\nComparison of percentages of positive cells between the different tissues was analyzed using a random effect logistic regression model. Comparison of MFI of positive cells between the different tissues was analyzed using ANOVA; *P â .05, **P â 01, ***P â 0001.\n\nFIG. 14 Expression of KIR, NKG2A/C, NCR, NKG2D and CD244 within the CD56 dim CDl6 + NK cell subset of different human tissues. Cells were gated on the CD45 + CD56 + CD3- population within CD45 + /SS gated cells to exclude T cells and endothelial cells from analysis.\n\nFigure 15 Proposed model for human NK cell development in vivo. Based on our data, we propose that precursor NK cells (stage 2) traffic from BM to LN, where commitment to the NK cell lineage takes place (stage 3a -> 3b) followed by in situ differentiation of NK cells with restricted maturation of the NK cell receptor repertoire. For further differentiation of committed NK cells,\n\nFigure 16 Mean fluorescence intensity of NKG2A expression following stage 4 to 5b.\n\nStages 1 and 2 are not committed to the NK cell lineage.\n\nStage 1 is commonly present in bone marrow (BM) and during ex- vivo NK cell generation and compromises subsets of G, N, L, P, F from which G, N are specific for BM tissue and L, P, F could be found in enriched CD34+ cells from umbilical cord blood (CB). Furthermore CB has exclusively E, K, M subsets in stage 1 and E, K subsets are present at week 1 and 2 of NK cell generation.\n\nBM bone marrow\n\nCB umbilical cord blood\n\nStage 2 cells are found also in CB tissue and share a central subset E with ex- vivo expanded CB cells during 3 weeks of culture.\n\nthe Cells from ex- vivo culture show an exclusive subset K also after week 1 and 2 of culture.\n\nStage 3a cells are found in various tissues such as BM, CB, peripheral blood (PB), spleen (SPL), inguinal lymph nodes (inLN), liver lymph nodes (LiLN) and during ex-vivo NK cell generation.\n\nPB peripheral blood\n\nSPL spleen\n\ninLN inguinal lymph nodes\n\nLiLN liver lymph nodes\n\nSeveral subsets such as K, M, N, J, 0, P could be identified. O is found only in SPL and BM whereas J is additionally also found in inLN and LiLN.\n\nBM, CB and PB share a central subset K, which is also present during 5 weeks of NK cell development.\n\nSPL, inLN and LiLN share the central P subset and in LiLN also the N subset is central.\n\nthe K subset is central in BM, CB and PB, it is exclusive for ex- vivo cultures compared to SPL, inLN and LiLN.\n\nEx-vivo cultures have exclusive subsets E, M compared with BM for week 1-3 and share P in the 1st week of culture and N subset for week 1-3.\n\nEx-vivo cultures have exclusive subsets E, M, N compared with PB in week 1-3 and share subset P in week 1-3.\n\nStage 3b cells are found in various tissues such as BM, CB, peripheral blood (PB), spleen (SPL), inguinal lymph nodes (inLN), liver lymph nodes (LiLN) and during ex-vivo NK cell generation.\n\nPB peripheral blood\n\nSPL spleen\n\ninLN inguinal lymph nodes\n\nLiLN liver lymph nodes\n\nEx-vivo cultures have exclusive subsets B, M, K, P compared with LiLN for week 3, B, M, K for week 4 and share N in the 3rd and 4th week of culture.\n\nB, M, K subsets are exclusively seen in week 5 of ex-vivo cultures.\n\nStage 4 cells are found in various tissues such as BM, CB, peripheral blood (PB), spleen (SPL), inguinal lymph nodes (inLN), liver lymph nodes (LiLN) and during ex-vivo NK cell generation.\n\nBM, PB and LiLN share central subsets J, B , which are present during 3 weeks of NK cell differentiation (week 3-5).\n\nCB, SPL and inLN share the central J subset.\n\nEx- vivo cultures have exclusive subsets K, M, compared with BM, PB and LiLN for week 4+5.\n\nB, K, M subsets are exclusively seen in week 4+5 of ex- vivo cultures compared to CB, SPL and inLN.\n\nStage 5a cells are found in various tissues such as BM, CB, peripheral blood (PB), spleen (SPL), inguinal lymph nodes (inLN), liver lymph nodes (LiLN) and during ex- vivo NK cell generation.\n\ntissues such as BM, CB, peripheral blood (PB), spleen (SPL), inguinal lymph nodes (inLN), liver lymph nodes (LiLN) and during ex- vivo NK cell generation.\n\nSeveral subsets such as K, M, J, B could be identified. No tissue specific subset was found.\n\nBM, PB, inLN and LiLN share central subsets J, B , which are present during 3 weeks of NK cell differentiation (week 3-5).\n\nCB and SPL share the central J subset compared to week 3-5 of culture.\n\nEx-vivo cultures have exclusive subset K compared with BM, inLN and LiLN during 4th and 5th week of culture. M subset is shared in week 5 of ex-vivo cultures.\n\nEx-vivo cultures have an exclusive subset B in the 3rd week of culture compared with CB and SPL and further exclusive subsets K, B during 4th and 5th week of culture.\n\nM subset is shared in week 5 of ex-vivo cultures.\n\nEx-vivo cultures subset subsets K compared with PB in the 4th week and share subsets K, M during the 5th week of culture.\n\nStage 5b cells are found in various tissues such as BM, CB, peripheral blood (PB), spleen (SPL), inguinal lymph nodes (inLN), liver lymph nodes (LiLN) and during ex-vivo NK cell generation.\n\nBM, CB, PB, SPL, inLN and LiLN share a central main subset M, which is present during 3 weeks of NK cell differentiation (week 3- 5).\n\nBM, CB and PB they share additionally the central small subset K compared to week 3-5 of culture.\n\nEx-vivo cultures have exclusive subset B compared with BM, CB and PB during 3rd and 5th week of culture.\n\nJ subset is shared in week 4+5 of ex-vivo cultures.\n\nFigure 25 Labelling of in vitro cultured cells of the invention (harvested at the w5 time point) with indium for in vivo homing study in NOD-SCID mice.\n\nFigure 26 SPECT results of whole NOD-SCID mice transplanted with labelled cells.\n\nUCB units have been obtained at birth after normal full-term delivery after written informed consent with regard of scientific use from the cord blood bank of the Radboud University Nijmegen Medical Center (RUNMC, Nijmegen, The Netherlands). UCB samples were stored at room temperature and processed within 24 h after collection. Before storage, the red blood cell content has been reduced using standard EloHAESÂ® separation and the mononuclear cells have been washed, cryopreserved and stored in liquid nitrogen [28]. Stored UCB units were thawed at 37Â°C and resuspended in thawing buffer consisting of CliniMACS PBS/EDTA buffer (Miltenyi Biotech, Bergisch Gladbach,\n\nUCB cells were incubated for 30 minutes at room temperature (RT) and subsequently centrifugated.\n\nUCB cells were resuspended in 8 ml washing buffer consisting of CliniMACS PBS/EDTA buffer, 0.5% HSA, 3.5 mM MgCh and 100 U/ml Pulmozyme and labeled for 30 minutes at RT with 0.75 ml CliniMACS CD34 reagent (Miltenyi Biotech) and 1 ml Nanogam (Sanquin blood bank, Amsterdam, The Netherlands). After incubation, the CD34-labeled UCB sample was washed and resuspended in 100 ml washing buffer.\n\nthe automated CliniMACS cell separator was equipped with a closed disposable CliniMACS tubing set type 161-01 (Miltenyi Biotech).\n\nthe CD34 + cell selection was performed using an automated program and after the enrichment procedure, the CD34 + cell fraction was collected, and the cell number and purity were analyzed by flow cytometry. Finally, the obtained CD34 + UCB cells were used directly for the NK cell generation bioprocess.\n\nThis medium consisted of Glycostem Basal Growth Medium (GBGM Â® ) for cord blood (CB) as used for the CD34 expansion step supplemented with 10% HS, the low-dose cytokine cocktail (as previously mentioned) and a new high-dose cytokine cocktail consisting of 20 ng/ml IL-7, 20 ng/ml SCF, 1000 U/ml IL-2 (ProleukinÂ®; Chiron, Miinchen, Germany) and 20 ng/ml IL-15 (CellGenix).\n\nthe cell density was checked two times a week and adjusted to 1.5 to 3.0xl0 6 cells/ml by the addition of GBGM Â® NK cell differentiation medium.\n\nthe conditions of the bioreactor were as follows: temperature 37 0 C, CO2 5%, airflow 0.1-0.2 1 min, rocking rate 10/min, rocking angle of 7Â°.\n\nCD34 + cells were incubated with the appropriate concentration of antibodies for 30 min at 4Â°C. After washing, cells were resuspended in Coulter Â® Isoton Â® II Diluent (Beckman Coulter) and analyzed using the Coulter FC500 flow cytometer (Beckman Coulter).\n\nCD45-FITC J33\n\nCD34- PE 581\n\nthe population of living CD34 + cells was determined by exclusion of 7AAD (Sigma, Bornem, Belgium) positive cells. Analysis was performed according to the most actual ISHAGE protocol.\n\nCD3-FITC (UCHT1) (Beckman Coulter, Woerden, The Netherlands); CD56-PE (NCAM16-2) (BD Biosciences Pharmingen, Breda, The Netherlands), anti-CD45-ECD (J33) (Beckman Coulter, Woerden, The Netherlands).\n\nCD16-FITC (NKP15), CD336(NKp44)-PE (Z231), CD3-ECD (UCHT1), CD337(NKp30)-PC5.5 (Z25), CD335(NKp46)-PE-Cy7 (BAB281), CD314(NKG2D)-APC (ON72), CD244(2B4)-APC-alexa700 (Cl.7.1), CD56-APC-Alexa750 (N901), CD161-PB (191B8), CD45-PO (J.33) (all provided by Beckman Coulter, Marseille , France). The acquisition analysis was performed on the NaviosTM flowcytometer and the data were further analyzed using the KaluzaTM software (all from Beckman Coulter, Miami, Florida, USA).\n\nCytogenetic analysis was performed on the final NK cell products according to standard methods. In total 20 metaphases were G-banded using trypsin and Giemsa (GTG) and were examined per case. Karyotypes were described according to ISCN 2009 [31] .\n\nMycoplasma detection was performed on final products using the MycoAlertÂ® Mycoplasma detection kit (Lonza, Rockland, USA) following the\n\nEndotoxin level in the final products was determined using the chromogenic Limulus Amebocyte Lysate (LAL) assay (Charles River Endosafe, Washington, SC, USA) following the manufacturer's guidelines by the Pharmacy\n\nCytokine levels in the final products were determined using ELISA. Briefly, Maxisorp 96-well plates (NUNC) were coated overnight with 1 ml of monoclonal coating antibody for IL-2, IL-7, IL- 15 and SCF (all from R&D systems, Abingdon, Oxon, UK). For sample detection, biotinylated antibodies were added for IL-2 (0.2 â g/ l polyclonal Ab), IL-7 (0.2 /ml polyclonal Ab), IL-15 (0.25 â /ml monoclonal Ab) and SCF (0.05 ml polyclonal Ab), respectively. The extinction was measured by the TiterTek Multiscan\n\nNK cell developmental stages samples were gated on the CD45 + CD3- population within CD45 + /SS gated cells to exclude T cells and endothelial cells (which may express CD34 but are CD45 negative 15 ) from analysis.\n\nNK cell receptor repertoire Table 5\n\ncells were further gated on CD56 + cells within the CD45 + CD3- population. Cell populations > 0.1% of the\n\nCD45 + CD3- population with a threshold of more than 50 cells were considered reliable.\n\nCell populations were considered to be present in a specific tissue when at least 3 out of 5 samples showed reliable results. Cell populations that did not suffice to these criteria were excluded from further (statistical) analysis. An overview of analyzed sample sizes is shown in Table 8.\n\nMFI fluorescence\n\nEnriched CD34 â UCB cells can be efficiently expanded using static cell culture bags\n\nCD56 + CD3- NK cells in bag cultures yielded in a purity of 71% â 9% ( Figure IB and Table 3). Because differentiation of the NK cell products was sub-optimal in the bag cultures, we next tested whether differentiation of the bag-expanded CD34 + cultures into the NK cell lineage could be improved using an automated bioreactor. Therefore, in a next set of experiments expanded CD34 + UCB cells were transferred at day 14 of culture into a bioreactor system with a minimal volume of 250 ml for starting the NK cell differentiation process.\n\ncytokine concentrations appeared to be below the specified range of â 25 pg/ml SCF, IL-7 and IL-15 and â 1 U/ml IL-2. Cytogenetic analysis showed that the NK cell products displayed a normal karyotype.\n\nDistinct NK cell developmental stages can be characterized through expression analysis of CD34, CD117, CD94 and CD56 antigens [50]. Based on that, we gated our samples on the CD45 + CD3- population within CD45 + /SS gated cells to exclude T cells and endothelial cells from analysis. Subsequently, cell subsets were first divided based on the expression of CD34 and CD 117. From there, in a second step, each subset was analyzed for CD56 and CD94 expression. Using this gating strategy, we were able to identify seven distinctive developmental stages in BM (Figure 9).\n\nCD34 expression is lost in stage 3a (CD34 CD117+CD56 CD94 ) followed by NK cell lineage commitment through CD56 acquisition in stage 3b (CD34-CD117 + CD56 + CD94-).\n\nNK cell lineage commitment cells gain CD94 expression and develop into immature CD56 br 3 â 4 ht NK cells (stage 4; CD34 CD117 + CD56 + CD94 + ).\n\nstage 4 CD34 CD117 + CD56 + CD94 +\n\nâ cells start to develop (stage 5a; CD34 CD117 CD56 + CD94 + ), followed by loss of CD94 expression in stage 5b (CD34 CD 117 CD56 + CD94 ).\n\nthe acquisition/loss of the different antigens and the presence of CD56 bri e ht/dim cells within each stage in BM are summarized in Table 6.\n\nCD133 is known as a stem cell antigen that may provide an alternative to CD34 for the selection and expansion of hematopoietic cells for transplantation [56]. Together with CD34, this antigen was only expressed within stages 1 and 2.\n\nCD33 has been described as an antigen for early NK cell development 17 and was expressed in stages 2 and 3a.\n\nthe CD244 receptor is suggested to be a co-receptor in activation of mature NK cells [58].\n\nCD244 was already expressed on CD34 + CD117 + stage 2 cells in BM.\n\nstages 3a and 3b CD244 expression remained present and the amount of CD244 + cells was increased to more than 98% in stages 4 to 5b.\n\nCD244 expression was only shown to be present at early stages of NK cell differentiation during in uiiro-induced human NK cell maturation [59].\n\nthe inhibitory NKG2A receptor shown to be expressed early during NK cell maturation [53], was detected starting from stage 4 just after NK cell commitment (stage 3b) till stage 5b.\n\nNK cell development starts in BM, followed by further maturation in LN, SPL and PB\n\nNK developmental stages can be found in other human tissues besides BM.\n\nCB cord blood\n\nPB peripheral blood\n\ninLN inguinal LN\n\nHNN liver LN\n\nSPL spleen\n\nNK cell developmental stages in CB were stage 5a followed by stage 5b.\n\nthe NK cell developmental stages mainly consisted of stage 5a and 5b cells.\n\nthe distribution of NK cell developmental stages in LN primarily contained stage 3a and stage 3b cells, and showed lower, but similar, frequencies of stages 4 to 5b.\n\nNK cell developmental stages in liLN and SPL consisted primarily of stages 4, 5a and 5b cells.\n\nCD33 expression was prolonged in CB, PB, and SPL until stage 3b.\n\nCD33 expression was even sustained after NK cell commitment until stage 4. The prolonged expression of CD33 in some distinct stages and tissues suggests tissue specific NK cell developmental subsets in situ.\n\ntissue specific NK cell subsets by the expression profile of CD33, we further analyzed if there are also tissue specific differences in the NK cell maturation pattern.\n\nlevel of NKG2A expression may be representative for the level of NK cell maturation [60,61]\n\nthe expression profile of NKG2A also showed a distinction between the different human tissues. In stage 4, all tissues contained more than 95% NKG2A + cells.\n\nNK cell subsets To further assess the maturity of the committed NK cell subsets, we analyzed the expression of various inhibitory and stimulatory NK cell receptors by using FCM panels 2 and 3 (Table 5). For analysis of the committed NK cell population, we gated on CD56 + cells within the CD45 + CD3\" population and subsequently analyzed the expression of killer immunoglobulin-like receptors (KIR), NKG2A/C, NKG2D, CD244 and natural cytotoxicity receptors (NCR; NKp30, NKp44, NKp46). These receptors trigger and modulate mature NK cell effector function through a balance between inhibitory (KIR, NKG2A) and stimulatory signals (NKG2C, NKG2D, CD244, NCR) [42,63].\n\nKIR killer immunoglobulin-like receptors\n\nNKp44 the amount of activating receptor positive cells, with the exception of NKp44, was also lower in liLN as compared with other tissues. This was also reflected within the CD56 dim CD16 + subset of liLN, showing lower amounts of NKG2D + , CD244 + and NKp30 + cells as compared with other tissues ( Figure 14). Thus, these results show that NK cell development in lymph nodes may differ in situ between LN at different anatomical locations and also other tissues.\n\nNCs Nucleated cells\n\nmin median and minimum\n\nmax maximum\n\nthe table summarize the generation of UCB-NK cell therapy products generated in static bags (Donor 7,8 and 9) or bioreactors cultures (Donor 10, 13, 15 and 16).\n\nthe table shows an overview o product release tests and product specifications for the ex-vivo generated NK cells using a closed cell culture process.\n\nFCM flow cytometric\n\nNK cells consisting of inhibitory and stimulatory receptors.\n\nInhibitory receptors contain KIR (CD158a, CD158b, CD158e1) and NKG2A (CD159a).\n\nStimulatory receptors contain NCR (CD335/336 337), NKG2C (CD159c), NKG2D (CD314), and 2B3 (CD244).\n\nNK cell developmental stages samples were gated on the CD45 + CD3 population within CD457SS gated cells to exclude T cells and endothelial cells from analysis. For each tissue, the following items are indicated: 1 Total cell number within the CD45 SS gate; 2 the amount of cells within the CD45 + CD3 \" gate and; 3 the total amount of cells covering all NK cell developmental stages. All cell numbers are shown in median (range).\n\nthe table shows all subsets during ex-vivo NK cell generation characterized with CD133, CD34, CD117, CD244, CD33, CD56,\n\nCD 133, CD244, CD33 and CD 159a The classification is further set as follows:\n\nthe NK cell development and immature NK cells are defined as a discrete set of stages (l-5b) or a combination of stages and/or a specific subset (L, F, G, E, M, N, K, J, 0, B) or combination of subsets subsets and/or a combination of stages and subsets.\n\nTable 10 Appearance of identified developmental subsets of discrete stages in human tissues and during e -vivo NK cell generation.\n\nCD133+ cell selection is an alternative to CD34+ cell selection for ex vivo expansion of hematopoietic stem cells. J Hematother Stem Cell Res. 2001;10(2):273- 281.\n\nHLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature.\n\nLandscapes\n\nHealth & Medical Sciences (AREA)\n\nEngineering & Computer Science (AREA)\n\nBiomedical Technology (AREA)\n\nLife Sciences & Earth Sciences (AREA)\n\nWood Science & Technology (AREA)\n\nOrganic Chemistry (AREA)\n\nChemical & Material Sciences (AREA)\n\nBiotechnology (AREA)\n\nZoology (AREA)\n\nBioinformatics & Cheminformatics (AREA)\n\nGenetics & Genomics (AREA)\n\nMicrobiology (AREA)\n\nCell Biology (AREA)\n\nImmunology (AREA)\n\nBiochemistry (AREA)\n\nGeneral Engineering & Computer Science (AREA)\n\nGeneral Health & Medical Sciences (AREA)\n\nHematology (AREA)\n\nMicro-Organisms Or Cultivation Processes Thereof (AREA)\n\nMedicines Containing Material From Animals Or Micro-Organisms (AREA)\n\nPCT/NL2012/050165 2011-03-18 2012-03-16 Generation of nk cells and nk-cell progenitors WO2012128622A1 (en)\n\nPriority Applications (6)\n\nApplication Number Priority Date Filing Date Title EP12711984.0A EP2686421B1 (en) 2011-03-18 2012-03-16 Generation of nk cells and nk-cell progenitors CA2830080A CA2830080C (en) 2011-03-18 2012-03-16 Generation of nk cells and nk-cell progenitors DK12711984.0T DK2686421T3 (da) 2011-03-18 2012-03-16 Generering af nk-celler og nk-celleforlÃ¸bere US14/005,168 US11118165B2 (en) 2011-03-18 2012-03-16 Generation of NK cells and NK-cell progenitors PL12711984T PL2686421T3 (pl) 2011-03-18 2012-03-16 Generowanie komÃ³rek nk i progenitorÃ³w komÃ³rek nk ES12711984T ES2856825T3 (es) 2011-03-18 2012-03-16 GeneraciÃ³n de cÃ©lulas NK y progenitores de cÃ©lulas NK\n\nApplications Claiming Priority (4)\n\nApplication Number Priority Date Filing Date Title NL2011050193 2011-03-18 NLPCT/NL2011/050193 2011-03-18 EP11162866 2011-04-18 EP11162866.5 2011-04-18\n\nPublications (1)\n\nPublication Number Publication Date WO2012128622A1 true WO2012128622A1 (en) 2012-09-27\n\nFamily\n\nID=45928983\n\nFamily Applications (1)\n\nApplication Number Title Priority Date Filing Date PCT/NL2012/050165 WO2012128622A1 (en) 2011-03-18 2012-03-16 Generation of nk cells and nk-cell progenitors\n\nCountry Status (7)\n\nCountry Link US (1) US11118165B2 (no) EP (1) EP2686421B1 (no) CA (1) CA2830080C (no) DK (1) DK2686421T3 (no) ES (1) ES2856825T3 (no) PL (1) PL2686421T3 (no) WO (1) WO2012128622A1 (no)\n\nCited By (13)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title WO2014028453A3 (en) * 2012-08-13 2014-10-09 Anthrogenesis Corporation Natural killer cells and uses thereof CN104509529A (zh) * 2013-10-08 2015-04-15 åº·å é¦æ¯ç¹å ¬å¸ ç¨äºå¨å­åè¿è¾nk-92ç»èç³»çæ¹æ¡åå¹å »åº WO2015054299A1 (en) * 2013-10-08 2015-04-16 Conkwest, Inc. Protocol and media for storage and transport of nk-92 cell line WO2017066530A1 (en) * 2015-10-15 2017-04-20 Anthrogensis Corporation Natural killer cells and ilc3 cells and uses thereof WO2017196657A1 (en) * 2016-05-07 2017-11-16 Anthrogenesis Corporation Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells CN108315299A (zh) * 2018-02-13 2018-07-24 åäº¬æ¯äºæ¾çç©ç§ææéå ¬å¸ ä¸ç§å³ç¨åå¼ä½nkç»èåºç½ç»å¨è¿åºç¨ç³»ç» CN111286488A (zh) * 2020-03-10 2020-06-16 æ²³åä¾¨åçå½ç§ææéå ¬å¸ ä¸ç§èªç¶æä¼¤ç»èä½å¤å¹å »æ¹æ³ WO2021006875A1 (en) 2019-07-08 2021-01-14 Nantkwest, Inc. Mononuclear cell derived nk cells CN114402065A (zh) * 2019-07-22 2022-04-26 æ ¼é·å æ¯è¿ªå§å»çç§äººæéå ¬å¸ ä½å¯åº¦ç»èå¹å » US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells US11559547B2 (en) 2017-03-03 2023-01-24 Imperial College Innovations Limited Natural killer cells US11566226B2 (en) 2017-03-28 2023-01-31 Imperial College Innovations Limited Natural killer cells EP4127142A4 (en) * 2020-03-26 2023-11-29 Honed Life Sciences, LLC ENHANCEMENT OF NK CELL PRODUCTION FROM STEM CELLS\n\nFamilies Citing this family (11)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta KR101697473B1 (ko) 2014-11-26 2017-01-18 ì£¼ìíì¬ ë ¹ì­ìë©ì  T ì¸í¬ë¥¼ ì´ì©í ìì°ì´í´ì¸í¬ì ë°°ìë°©ë² EP3446117A4 (en) * 2016-01-29 2019-11-20 Tract Therapeutics, Inc. SELECTION, EXPANSION AND USE OF IMMUNE CELLS JP6647240B2 (ja) * 2017-05-12 2020-02-14 ç±³æºãåå é«æ´»æ§ï½ï½ç´°èãããã³ãã®å©ç¨ US11446329B2 (en) * 2017-11-01 2022-09-20 Restem Llc Natural killer cell adoptive transfer therapy for the elimination of senescent PBMCs, reduction of inflammatory cytokines and treatment of IBS KR102265437B1 (ko) * 2017-11-24 2021-06-15 ìë£ë²ì¸ ì±ê´ìë£ì¬ë¨ Nk ë°°ìì© ì¡°ì±ë¬¼ ë° ì´ë¥¼ ì´ì©íì¬ nk ì¸í¬ë¥¼ ë°°ìíë ë°©ë² IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment WO2019182392A1 (ko) * 2018-03-23 2019-09-26 ì£¼ìíì¬ ë ¹ì­ìë©ì  ìì°ì´í´ì¸í¬ì ì ì¡°ë°©ë² EP4032972A4 (en) * 2019-09-18 2024-07-24 Slbigen Inc GENETICALLY MODIFIED NK CELL LINE TRANSDUCED WITH A GENE ENCODING A NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells US20230214822A1 (en) * 2022-01-05 2023-07-06 Mastercard International Incorporated Computer-implemented methods and systems for authentic user-merchant association and services\n\nCitations (3)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title WO2008118020A1 (en) * 2007-03-27 2008-10-02 Ipd-Therapeutics B.V. Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics WO2011080740A1 (en) * 2009-12-29 2011-07-07 Gamida-Cell Ltd. Methods for enhancing natural killer cell proliferation and activity WO2011103882A1 (en) * 2010-02-24 2011-09-01 Ingo Schmidt-Wolf Method for the generation of a cik cell and nk cell population\n\nFamily Cites Families (3)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title PT1941027E (pt) * 2005-09-28 2014-10-09 Ipd Therapeutics B V MÃ©todos e meios para proliferaÃ§Ã£o de cÃ©lulas estaminais e subsequente geraÃ§Ã£o e expansÃ£o de cÃ©lulas progenitoras, bem como produÃ§Ã£o de cÃ©lulas efectoras como produtos terapÃªuticos clÃ­nicos WO2008023874A1 (en) * 2006-08-23 2008-02-28 Binex Co., Ltd. Manufacturing method of activated lymphocytes for immunotherapy KR20180086204A (ko) * 2015-11-05 2018-07-30 ê¸ë¦¬ì½ì¤í  ë¼ë¼í¨í±ì¤ ë¹.ë¸ì´. ë©´ì­ì¹ë£ë²ì ì¬ì©íê¸° ìí ì¡°ì±ë¬¼\n\n2012\n\n2012-03-16 ES ES12711984T patent/ES2856825T3/es active Active\n\n2012-03-16 EP EP12711984.0A patent/EP2686421B1/en active Active\n\n2012-03-16 PL PL12711984T patent/PL2686421T3/pl unknown\n\n2012-03-16 WO PCT/NL2012/050165 patent/WO2012128622A1/en active Application Filing\n\n2012-03-16 US US14/005,168 patent/US11118165B2/en active Active\n\n2012-03-16 CA CA2830080A patent/CA2830080C/en active Active\n\n2012-03-16 DK DK12711984.0T patent/DK2686421T3/da active\n\nPatent Citations (3)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title WO2008118020A1 (en) * 2007-03-27 2008-10-02 Ipd-Therapeutics B.V. Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics WO2011080740A1 (en) * 2009-12-29 2011-07-07 Gamida-Cell Ltd. Methods for enhancing natural killer cell proliferation and activity WO2011103882A1 (en) * 2010-02-24 2011-09-01 Ingo Schmidt-Wolf Method for the generation of a cik cell and nk cell population\n\nNon-Patent Citations (74)\n\n* Cited by examiner, â Cited by third party Title \"An International System for Human Cytogenetic Nomenclature.\", 2009 AHARON G FREUD ET AL: \"Evidence for discrete stages of human natural killer cell differentiation in vivo\", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 203, no. 4, 17 April 2006 (2006-04-17), ROCKEFELLER UNIVERSITY PRESS, US, pages 1033 - 1043, XP002659021, ISSN: 0022-1007, [retrieved on 20060410], DOI: 10.1084/JEM.20052507 * AKTAS M; BUCHHEISER A; HOUBEN A; REIMANN V; RADKE T ET AL.: \"Good manufacturing practice-grade production of unrestricted somatic stem cell from fresh cord blood\", CYTOTHERAPY, vol. 12, 2010, pages 338 - 348 ALTER G; MALENFANT JM; ALTFELD M: \"CD 107a as a functional marker for the identification of natural killer cell activity.\", J IMMUNOL METHODS, vol. 294, 2004, pages 15 - 22 BARKHOLT L; ALICI E; CONRAD R; SUTLU T; GILLJAM M ET AL.: \"Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.\", IMMUNOTHERAPY, vol. 1, 2009, pages 753 - 764 BERG M; LUNDQVIST A; MCCOY P, JR.; SAMSEL L; FAN Y ET AL.: \"Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.\", CYTOTHERAPY, vol. 11, 2009, pages 341 - 355 BRAUD VM; ALLAN DS; O'CALLAGHAN CA ET AL.: \"HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.\", NATURE, vol. 391, no. 6669, 1998, pages 795 - 799 CARLENS S ET AL: \"A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells\", HUMAN IMMUNOLOGY, vol. 62, no. 10, 1 October 2001 (2001-10-01), NEW YORK, NY, US, pages 1092 - 1098, XP002276286, ISSN: 0198-8859, DOI: 10.1016/S0198-8859(01)00313-5 * CARLENS S; GILLJAM M; CHAMBERS BJ; ASCHAN J; GUVEN H ET AL.: \"A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.\", HUM IMMUNOL, vol. 62, 2001, pages 1092 - 1098 CHISARI FV.: \"Cytotoxic T cells and viral hepatitis\", J CLIN INVEST., vol. 99, no. 7, 1997, pages 1472 - 1477 COLUCCI ET AL., NATURE REVIEWS IMMUNOLOGY, vol. 3, 2003, pages 413 - 428 COLUCCI F; CALIGIURI MA; DI SANTO JP.: \"What does it take to make a natural killer?\", NAT REV IMMUNOL., vol. 3, no. 5, 2003, pages 413 - 425 COOLEY S; XIAO F; PITT M ET AL.: \"A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self MHC is developmentally immature.\", BLOOD, 2007 COOPER MA; FEHNIGER TA; CALIGIURI MA.: \"The biology of human natural killer-cell subsets.\", TRENDS IMMUNOL., vol. 22, no. 11, 2001, pages 633 - 640 DALLE JH; MENEZES J; WAGNER E ET AL.: \"Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections.\", PEDIATR RES., vol. 57, 2005, pages 649 - 655 DELANEY C; HEIMFELD S; BRASHEM-STEIN C; VOORHIES H; MANGER RL ET AL.: \"Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution\", NAT MED, vol. 16, 2010, pages 232 - 236 DI SANTO JP.: \"Natural killer cell developmental pathways: a question of balance.\", ANNU REV IMMUNOL., vol. 24, 2006, pages 257 - 286 DI SANTO, ANNU. REV. IMMUNOL., vol. 24, 2006, pages 257 - 286 EICHLER H; BECK C; SCHRODER B; NGUYEN XD; KLUTER H: \"Nonobese diabetic-severe combined immunodeficient mice transplantation of volume-reduced and thawed umbilical cord blood transplants following closed-system immunomagnetic cell selection.\", TRANSFUSION, vol. 42, 2002, pages 1285 - 1292 EISSENS DN; SCHAAP NP; PREIJERS FW ET AL.: \"CD3(+)/CD19(+)-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A\", LEUKEMIA, vol. 24, no. 3, 2010, pages 583 - 591 FARAG SS; CALIGIURI MA.: \"Human natural killer cell development and biology.\", BLOOD REV., vol. 20, no. 3, 2006, pages 123 - 137 FEHNIGER TA; COOPER MA; NUOVO GJ ET AL.: \"CD56bright natural killer cells are present in human lymph nodes and are activated by T cell- derived IL-2: a potential new link between adaptive and innate immunity.\", BLOOD., vol. 101, no. 8, 2003, pages 3052 - 3057 FERLAZZO G; THOMAS D; LIN SL ET AL.: \"The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig- like receptors and become cytolytic.\", J IMMUNOL., vol. 172, no. 3, 2004, pages 1455 - 1462 FREUD AG; BECKNELL B; ROYCHOWDHURY S ET AL.: \"A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells.\", IMMUNITY, vol. 22, no. 3, 2005, pages 295 - 304 FREUD AG; CALIGIURI MA: \"Human natural killer cell development\", IMMUNOL REV., vol. 214, 2006, pages 56 - 72 FREUD AG; YOKOHAMA A; BECKNELL B ET AL.: \"Evidence for discrete stages of human natural killer cell differentiation in vivo.\", J EXP MED., vol. 203, no. 4, 2006, pages 1033 - 1043 FUJISAKI H; KAKUDA H; SHIMASAKI N; IMAI C; MA J ET AL.: \"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.\", CANCER RES, vol. 69, 2009, pages 4010 - 4017 GIORDANO R; LAZZARI L; MONTEMURRO T; LECCHI L; PORRETTI L ET AL.: \"Clinical-grade cell purification from thawed cord blood: an example of translational research.\", BONE MARROW TRANSPLANT, vol. 32, 2003, pages 965 - 966 IYENGAR R; HANDGRETINGER R; BABARIN-DORNER A; LEIMIG T; OTTO M ET AL.: \"Purification of human natural killer cells using a clinical-scale immunomagnetic method.\", CYTOTHERAPY, vol. 5, 2003, pages 479 - 484 JAN SPANHOLTZ ET AL: \"Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process\", PLOS ONE, vol. 6, no. 6, E20740, 16 June 2011 (2011-06-16), pages 1 - 11, XP055014138, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0020740 * KAISER BK; PIZARRO JC; KERNS J; STRONG RK: \"Structural basis for NKG2A/CD94 recognition of HLA-E.\", PROC NATL ACAD SCI U S A., vol. 105, no. 18, 2008, pages 6696 - 6701 KLINGEMANN HG; MARTINSON J: \"Ex vivo expansion of natural killer cells for clinical applications.\", CYTOTHERAPY, vol. 6, 2004, pages 15 - 22 KOBARI L; GIARRATANA MC; PFLUMIO F ET AL.: \"CD133+ cell selection is an alternative to CD34+ cell selection for ex vivo expansion of hematopoietic stem cells.\", J HEMATOTHER STEM CELL RES., vol. 10, no. 2, 2001, pages 273 - 281 KOEHL U; ESSER R; ZIMMERMANN S; TONN T; KOTCHETKOV R ET AL.: \"Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children\", KLIN PADIATR, vol. 217, 2005, pages 345 - 350 LANIER, ANNU. REV. IMMUNOL., vol. 23, 2005, pages 225 - 274 LAPIERRE V; PELLEGRINI N; BARDEY I; MALUGANI C; SAAS P ET AL.: \"Cord blood volume reduction using an automated system (Sepax) vs. a semi automated system (Optipress II) and a manual method (hydroxyethyl starch sedimentation) for routine cord blood banking: a comparative study.\", CYTOTHERAPY, vol. 9, 2007, pages 165 - 169 LECCHI L; PEREGO L; GARCEA F; RATTI I; BRASCA M ET AL.: \"Ten-year quality control of a semiautomated procedure of cord blood unit volume reduction.\", TRANSFUSION, vol. 49, 2009, pages 563 - 569 LJUNGGREN HG; MALMBERG KJ: \"Prospects for the use of NK cells in immunotherapy of human cancer.\", NAT REV IMMUNOL, vol. 7, 2007, pages 329 - 339 LJUNGGREN HG; MALMBERG KJ: \"Prospects for the use of NK cells in immunotherapy of human cancer.\", NAT REV IMMUNOL., vol. 7, no. 5, 2007, pages 329 - 339 MALE V; HUGHES T; MCCLORY S ET AL.: \"Immature NK cells, capable of producing IL-22, are present in human uterine mucosa.\", J IMMUNOL., vol. 185, no. 7, 2010, pages 3913 - 3918 MCKENNA DH; SUMSTAD D; BOSTROM N; KADIDLO DM; FAUTSCH S ET AL.: \"Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience.\", TRANSFUSION, vol. 47, 2007, pages 520 - 528 MCNIECE IK; STONEY GB; KERN BP; BRIDDELL RA: \"CD34+ cell selection from frozen cord blood products using the Isolex 300i and CliniMACS CD34 selection devices\", J HEMATOTHER, vol. 7, 1998, pages 457 - 461 MEYER-MONARD S; PASSWEG J; SIEGLER U; KALBERER C; KOEHL U ET AL.: \"Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation.\", TRANSFUSION, vol. 49, 2009, pages 362 - 371 MILLER JS; SOIGNIER Y; PANOSKALTSIS-MORTARI A; MCNEARNEY SA; YUN GH ET AL.: \"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.\", BLOOD, vol. 105, 2005, pages 3051 - 3057 MOROSO V; METSELAAR HJ; MANCHAM S ET AL.: \"Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation.\", LIVER TRANSPL., vol. 16, no. 7, 2010, pages 895 - 908 NGUYEN S; DHEDIN N; VERNANT JP ET AL.: \"NK cell reconstitution after haploidentical hematopoietic stem cell transplants: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect.\", BLOOD, vol. 105, no. 10, 2005, pages 4135 - 4142 OVERES IM; DE RIJKE B; VAN HORSSEN-ZOETBROOD A; FREDRIX H; DE GRAAF AO ET AL.: \"Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis.\", BR J HAEMATOL, vol. 141, 2008, pages 799 - 807 PAPAMICHAIL M; PEREZ SA; GRITZAPIS AD; BAXEVANIS CN.: \"Natural killer lymphocytes: biology, development, and function.\", CANCER IMMUNOL IMMUNOTHER., vol. 53, no. 3, 2004, pages 176 - 186 PASSWEG JR; KOEHL U; UHAREK L; MEYER-MONARD S; TICHELLI A: \"Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation.\", BEST PRACT RES CLIN HAEMATOL, vol. 19, 2006, pages 811 - 824 PERUZZI G; MASILAMANI M; BORREGO F; COLIGAN JE.: \"Endocytosis as a mechanism of regulating natural killer cell function: unique endocytic and trafficking pathway for CD94/NKG2A.\", IMMUNOL RES., vol. 43, no. 1-3, 2009, pages 210 - 222 QUEROL S; CAPMANY G; AZQUETA C; GABARRO M; FORNAS 0 ET AL.: \"Direct immunomagnetic method for CD34+ cell selection from cryopreserved cord blood grafts for ex vivo expansion protocols.\", TRANSFUSION, vol. 40, 2000, pages 625 - 631 RAULET DH: \"Development and tolerance of natural killer cells.\", CURR OPIN IMMUNOL., vol. 11, no. 2, 1999, pages 129 - 134 ROBERTSON MJ; RITZ J: \"Biology and clinical relevance of human natural killer cells.\", BLOOD, vol. 76, no. 12, 1990, pages 2421 - 2438 RUBINSTEIN P; DOBRILA L; ROSENFIELD RE; ADAMSON JW; MIGLIACCIO G ET AL.: \"Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution\", PROC NATL ACAD SCI U S A, vol. 92, 1995, pages 10119 - 10122 RUBNITZ JE; INABA H; RIBEIRO RC; POUNDS S; ROONEY B ET AL.: \"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.\", J CLIN ONCOL, vol. 28, 2010, pages 955 - 959 RUGGERI L; CAPANNI M; URBANI E; PERRUCCIO K; SHLOMCHIK WD ET AL.: \"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants\", SCIENCE, vol. 295, 2002, pages 2097 - 2100 SHILLING HG; MCQUEEN KL; CHENG NW ET AL.: \"Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation.\", BLOOD, vol. 101, no. 9, 2003, pages 3730 - 3740 SIEGLER U; MEYER-MONARD S; JORGER S; STERN M; TICHELLI A ET AL.: \"Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.\", CYTOTHERAPY, 2010 SIVORI S; FALCO M; MARCENARO E ET AL.: \"Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation.\", PROC NATL ACAD SCI U S A., vol. 99, no. 7, 2002, pages 4526 - 4531 SIVORI S; PAROLINI S; FALCO M ET AL.: \"2B4 functions as a co-receptor in human NK cell activation\", EUR J IMMUNOL., vol. 30, no. 3, 2000, pages 787 - 793 SOLVES P; MIRABET V; CARBONELL-UBEROS F; SOLER MA; ROIG R: \"Automated separation of cord blood units in top and bottom bags using the Compomat G4.\", CLIN LAB HAEMATOL, vol. 28, 2006, pages 202 - 207 SOLVES P; MIRABET V; PLANELLES D; BLASCO I; PERALES A ET AL.: \"Red blood cell depletion with a semiautomated system or hydroxyethyl starch sedimentation for routine cord blood banking: a comparative study.\", TRANSFUSION, vol. 45, 2005, pages 867 - 873 SPANHOLTZ J ET AL: \"High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy\", PLOS ONE, vol. 5, no. 2, E9221, 15 February 2010 (2010-02-15), PUBLIC LIBRARY OF SCIENCE USA, pages 1 - 13, XP002665360, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0009221 * SPANHOLTZ J; TORDOIR M; EISSENS D ET AL.: \"High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy\", PLOS ONE, vol. 5, no. 2, 2010, pages E9221 TANAKA H; KAI S; YAMAGUCHI M ET AL.: \"Analysis of natural killer (NK) cell activity and adhesion molecules on NK cells from umbilical cord blood.\", EUR J HAEMATOL., vol. 71, no. 1, 2003, pages 29 - 38 VIVIER E; NUNES JA; VELY F: \"Natural killer cell signaling pathways.\", SCIENCE, vol. 306, 2004, pages 1517 - 1519 WANG Y; XU H; ZHENG X ET AL.: \"High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity.\", CELL MOL IMMUNOL., vol. 4, no. 5, 2007, pages 377 - 382 YOKOYAMA WM; KIM S; FRENCH AR: \"The dynamic life of natural killer cells.\", ANNU REV IMMUNOL., vol. 22, 2004, pages 405 - 429 YU J; MAO HC; WEI M ET AL.: \"CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK cell subsets.\", BLOOD, 2009 YU S; NAKAFUSA Y; FLYE MW.: \"Portal vein administration of donor cells promotes peripheral allospecific hyporesponsiveness and graft tolerance\", SURGERY, vol. 116, no. 2, 1994, pages 229 - 234 ZHAO XY; HUANG XJ; LIU KY; XU LP; LIU DH.: \"Reconstitution of Natural Killer Cell Receptor Repertoires after Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Transplantation: Analyses of CD94:NKG2A and Killer Immunoglobulin-Like Receptor Expression and Their Associations with Clinical Outcome\", BIOL BLOOD MARROW TRANSPLANT., vol. 13, no. 6, 2007, pages 734 - 744\n\nCited By (16)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title WO2014028453A3 (en) * 2012-08-13 2014-10-09 Anthrogenesis Corporation Natural killer cells and uses thereof US20150225697A1 (en) * 2012-08-13 2015-08-13 Anthrogenesis Corporation Natural killer cells and uses thereof CN105008516A (zh) * 2012-08-13 2015-10-28 äººç±»èµ·æºå ¬å¸ èªç¶æä¼¤ç»èåå ¶ç¨é CN104509529A (zh) * 2013-10-08 2015-04-15 åº·å é¦æ¯ç¹å ¬å¸ ç¨äºå¨å­åè¿è¾nk-92ç»èç³»çæ¹æ¡åå¹å »åº WO2015054299A1 (en) * 2013-10-08 2015-04-16 Conkwest, Inc. Protocol and media for storage and transport of nk-92 cell line WO2017066530A1 (en) * 2015-10-15 2017-04-20 Anthrogensis Corporation Natural killer cells and ilc3 cells and uses thereof WO2017196657A1 (en) * 2016-05-07 2017-11-16 Anthrogenesis Corporation Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells US11180731B2 (en) 2016-05-07 2021-11-23 Celularity Inc. Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells US11559547B2 (en) 2017-03-03 2023-01-24 Imperial College Innovations Limited Natural killer cells US11566226B2 (en) 2017-03-28 2023-01-31 Imperial College Innovations Limited Natural killer cells CN108315299A (zh) * 2018-02-13 2018-07-24 åäº¬æ¯äºæ¾çç©ç§ææéå ¬å¸ ä¸ç§å³ç¨åå¼ä½nkç»èåºç½ç»å¨è¿åºç¨ç³»ç» US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells WO2021006875A1 (en) 2019-07-08 2021-01-14 Nantkwest, Inc. Mononuclear cell derived nk cells CN114402065A (zh) * 2019-07-22 2022-04-26 æ ¼é·å æ¯è¿ªå§å»çç§äººæéå ¬å¸ ä½å¯åº¦ç»èå¹å » CN111286488A (zh) * 2020-03-10 2020-06-16 æ²³åä¾¨åçå½ç§ææéå ¬å¸ ä¸ç§èªç¶æä¼¤ç»èä½å¤å¹å »æ¹æ³ EP4127142A4 (en) * 2020-03-26 2023-11-29 Honed Life Sciences, LLC ENHANCEMENT OF NK CELL PRODUCTION FROM STEM CELLS\n\nAlso Published As\n\nPublication number Publication date CA2830080C (en) 2021-10-26 EP2686421A1 (en) 2014-01-22 CA2830080A1 (en) 2012-09-27 EP2686421B1 (en) 2020-12-23 DK2686421T3 (da) 2021-03-08 US11118165B2 (en) 2021-09-14 ES2856825T3 (es) 2021-09-28 US20140080148A1 (en) 2014-03-20 PL2686421T3 (pl) 2021-05-31\n\nSimilar Documents\n\nPublication Publication Date Title EP2686421B1 (en) 2020-12-23 Generation of nk cells and nk-cell progenitors US20210054338A1 (en) 2021-02-25 Ex vivo nk cell differentiation from cd34+ hematopoietic cells Spanholtz et al. 2011 Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process US20070218552A1 (en) 2007-09-20 Method for Producing Red Blood Cells US20230355676A1 (en) 2023-11-09 Highly active nk cell and use thereof Euchner et al. 2021 Natural killer cells generated from human induced pluripotent stem cells mature to CD56brightCD16+ NKp80+/-in-vitro and express KIR2DL2/DL3 and KIR3DL1 US20230106769A1 (en) 2023-04-06 Serum-free medium and culturing method suited for culturing blood cells such as human hematopoietic stem cells JP2014523741A (ja) 2014-09-18 è¡å°æ¿ç£çã®ããã®å·¨æ ¸çåé§ç´°è AU2020211441B2 (en) 2023-06-29 A method for producing a cell population including nk cells CN114402065A (zh) 2022-04-26 ä½å¯åº¦ç»èå¹å » KR100818215B1 (ko) 2008-04-01 ï¼£ï½ï¼ï¼ìì± ì¤ê¸°ì¸í¬ë¡ë¶í° ï½ ìíêµ¬ ì êµ¬ì²´ë¥¼ ì ì¡°íë ë°©ë² JP6697611B2 (ja) 2020-05-20 é«æ´»æ§ï½ï½ç´°èãããã³ãã®å©ç¨ JP2020108405A (ja) 2020-07-16 é«æ´»æ§ï½ï½ç´°èãããã³ãã®å©ç¨ KR20220063446A (ko) 2022-05-17 ë§ì´íì¡ ë¨íµì¸í¬ë¡ë¶í° ìì°ì´í´ì¸í¬ë¡ì ë¶íê³¼ì  ì¤ ë¶í ëë ì¦ìì ì¦ì§ìí¤ë ë°©ë² WO2020152661A1 (ja) 2020-07-30 ï¼®ï½ç´°èãå«ãç´°èéå£ã®è£½é æ¹æ³ JP2023153286A (ja) 2023-10-17 ï¼®ï½ç´°èãå«ãç´°èéå£ã®è£½é æ¹æ³ Giebel 0 Human multipotent hematopoietic progenitor cell expansion is neither supported in endothelial and endothelial/mesenchymal co-cultures nor in nSG mice Spanholtz 2013 NK: natural born killers: natural killer cell immunotherapy: from bench to bedside\n\nLegal Events\n\nDate Code Title Description 2012-11-14 121 Ep: the epo has been informed by wipo that ep was designated in this application\n\nRef document number: 12711984\n\nCountry of ref document: EP\n\nKind code of ref document: A1\n\n2013-09-12 ENP Entry into the national phase\n\nRef document number: 2830080\n\nCountry of ref document: CA\n\n2013-09-18 NENP Non-entry into the national phase\n\nRef country code: DE\n\n2013-10-18 WWE Wipo information: entry into national phase\n\nRef document number: 2012711984\n\nCountry of ref document: EP\n\n2013-12-02 WWE Wipo information: entry into national phase\n\nRef document number: 14005168\n\nCountry of ref document: US"
    }
}